Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of the Earnings Call of the Company held on Tuesday, May 27, 2025
NH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Narayana Hrudayalaya has filed the transcript of its Q4 FY25 earnings call. Key takeaways: (1) Cayman business ($45M revenue run-rate) is now considered a sustainable base, with margins likely capped at ~45% as focus shifts to revenue growth rather than margin expansion. (2) India margins are improving as general ward beds are being upgraded to private/semi-private rooms, with management indicating further improvement is reasonable. (3) Clinic/insurance losses stood at Rs 65 crore in FY25 and are expected to rise further as expansion continues, with a ~Rs 400 crore cumulative investment planned over 3-4 years. (4) FY26 capex guidance: ~Rs 300 crore on maintenance/replacement and ~Rs 450 crore on greenfield/brownfield expansion, partly funded by debt (60-65% of new project capex through debt). (5) New venture with 2070 Health to set up retail chemotherapy centers, first center soft-launching in Gurgaon (~5,000 sq ft). (6) International patient revenue has not bottomed out yet and may trend to zero.
Mixed signals for shareholders. Positive: India margin trajectory improving through bed-mix upgrades and higher-complexity procedures; strong Cayman ramp-up; Rs 1,600 crore cash reserves support growth. Negative: Management declined to give forward growth guidance, evaded key questions on insurance breakeven and expansion targets, and signaled rising losses in clinic/insurance segment. Near-term impact likely neutral, with FY26 capex execution and debt-funded expansion being the key swing factors.